ProGenis Pharmaceuticals
Bentley
About ProGenis Pharmaceuticals
ProGenis Pharmaceuticals is a biotechnology firm specializing in precision RNA medicines targeted at inherited and acquired rare diseases as well as type 2 diabetes, multiple sclerosis, Duchenne muscular dystrophy, and Rett syndrome.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $304.1K
- Last round: Grant (Nov 2025)
- Website: progenispharma.com
Industries & Categories
Manufacturing, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/progenis-pharmaceuticals-162170 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.